Clinical Trials

Comparing Immune Responses to Topical Imiquimod

Condition:   Actinic Keratoses
Intervention:   Drug: Imiquimod
Sponsor:   University of California, Davis
Recruiting
Mon, 22 Mar 2021 12:00:00 EDT

Imiquimod for Preventing Keloid Recurrence

Condition:   Keloid
Intervention:   Drug: Imiquimod 5% cream
Sponsor:   University of Pennsylvania
Terminated
Fri, 30 Nov 2018 12:00:00 EST

Open-label Study to Evaluate Clearance of Superficial Basal Cell Carcinoma After Use of Imiquimod 5% Cream

Condition:   Superficial Basal Cell Carcinoma
Intervention:   Drug: Imiquimod 5% cream
Sponsor:   Graceway Pharmaceuticals, LLC
Completed
Mon, 19 Sep 2005 12:00:00 EDT

Combination Therapy of Topical Imiquimod Plus Multipeptide Vaccination for Cutaneous Metastases of Melanoma

Condition:   Melanoma
Interventions:   Biological: MELITAC 12.1;   Drug: Imiquimod
Sponsor:   University of Virginia
Completed
Wed, 22 Dec 2010 12:00:00 EST

The Effects of Aldara as an Adjunct to Laser Treatment

Condition:   Port Wine Stains
Interventions:   Drug: Imiquimod;   Drug: non-medicated petroleum cream
Sponsors:   Henry Vasconez;   Graceway Pharmaceuticals, LLC
Terminated
Fri, 18 Sep 2009 12:00:00 EDT

Imiquimod for Breast Cancer Patients With Chest Wall Recurrence or Skin Metastases

Conditions:   Breast Cancer;   Breast Neoplasms
Intervention:   Drug: Imiquimod
Sponsor:   NYU Langone Health
Completed
Tue, 12 May 2009 12:00:00 EDT

Topical Imiquimod vs. LEEP for Women With Carcinoma In-situ of the Cervix

Condition:   Cervical Intraepithelial Neoplasia
Interventions:   Drug: Imiquimod;   Procedure: Loop Electrosurgical Excision Procedure
Sponsor:   United States Naval Medical Center, San Diego
Completed
Mon, 05 May 2014 12:00:00 EDT

Radiotherapy or Imiquimod in Complex Lentigo Maligna

Condition:   Lentigo Maligna
Interventions:   Drug: Imiquimod;   Radiation: Radiotherapy
Sponsors:   Melanoma and Skin Cancer Trials Limited;   Melanoma Institute Australia
Recruiting
Fri, 20 Mar 2015 12:00:00 EDT

Open-Label Safety Study to Evaluate Imiquimod Cream, 5% for Large Areas of Actinic Keratosis

Condition:   Keratosis
Intervention:   Drug: imiquimod cream
Sponsor:   Graceway Pharmaceuticals, LLC
Completed
Fri, 01 Jul 2005 12:00:00 EDT

Imiquimod 3.75% Cream in Combination With Cryotherapy in the Treatment of Hypertrophic Actinic Keratoses

Condition:   Actinic Keratosis
Intervention:   Drug: Cryotherapy alone to Left arm plus cryotherapy + imiquimod to Right arm
Sponsors:   Frankel, Amylynne, M.D.;   Graceway Pharmaceuticals, LLC
Unknown status
Wed, 27 Oct 2010 12:00:00 EDT

ITIC (Imiquimod Therapy in Cervical Intraepithelial Neoplasia)-Trial

Condition:   Cervical Intraepithelial Neoplasia
Intervention:   Drug: Topical imiquimod therapy
Sponsor:   Medical University of Vienna
Completed
Fri, 17 Jul 2009 12:00:00 EDT

Topical 5% Imiquimod Cream for Vulvar Paget's Disease

Condition:   Paget Disease, Extramammary
Interventions:   Drug: Imiquimod;   Drug: paracetamol;   Drug: lidocaine in Vaseline ointment
Sponsors:   University Medical Center Nijmegen;   Leiden University Medical Center;   University Medical Center Groningen;   Erasmus Medical Center;   The Netherlands Cancer Institute;   UMC Utrecht;   Catharina Ziekenhuis Eindhoven
Completed
Wed, 11 Mar 2015 12:00:00 EDT

Topical Imiquimod Versus Conization to Treat Cervical Intraepithelial Neoplasia

Condition:   Cervical Intraepithelial Neoplasia
Interventions:   Drug: Topical Imiquimod;   Procedure: Conization
Sponsors:   Medical University of Vienna;   Medical University of Graz;   Medical University Innsbruck;   Krankenhaus Barmherzige Schwestern Linz;   Salzburger Landeskliniken
Terminated
Wed, 26 Jan 2011 12:00:00 EST

Treatment Study for Actinic Cheilitis Comparing Imiquimod 5% and Photodynamic Therapy

Condition:   Actinic Cheilitis
Interventions:   Drug: Imiquimod 5%;   Procedure: Photodynamic therapy
Sponsors:   Norwegian University of Science and Technology;   St. Olavs Hospital
Completed
Tue, 24 Feb 2009 12:00:00 EST

Topical Imiquimod Cream in Combination With Cryotherapy for the Treatment of Actinic Keratoses

Condition:   Actinic Keratoses
Intervention:   Drug: imiquimod 5% cream
Sponsor:   Rigel Dermatology
Completed
Fri, 17 Oct 2008 12:00:00 EDT

Comparison of Treatment of Cervical Intraepithelial Lesions With Imiquimod or LLETZ

Condition:   Intraepithelial Neoplasia, Cervical
Interventions:   Drug: Aldara 5% Topical Cream;   Procedure: LLETZ
Sponsor:   University Medical Centre Maribor
Active, not recruiting
Mon, 26 Apr 2021 12:00:00 EDT

NY-ESO-1 Protein Vaccine With Imiquimod in Melanoma (Adjuvant Setting)

Condition:   Malignant Melanoma
Interventions:   Drug: Imiquimod;   Biological: NY-ESO-1 protein
Sponsors:   Ludwig Institute for Cancer Research;   Cancer Research Institute (CRI)
Completed
Fri, 02 Sep 2005 12:00:00 EDT

Imiquimod to Detect Residual Lesions and Prevent Recurrence of Lentigo Maligna

Condition:   Lentigo Maligna
Intervention:   Drug: Imiquimod
Sponsor:   Medical University of Graz
Active, not recruiting
Wed, 17 Mar 2010 12:00:00 EDT

Imiquimod Versus Photodynamic Therapy of Actinic Keratoses in Organ Transplant Recipients

Condition:   Actinic Keratoses
Interventions:   Other: photodynamic therapy;   Drug: imiquimod 5% cream
Sponsor:   Medical University of Vienna
Terminated
Fri, 24 Feb 2012 12:00:00 EST

Surgery Versus Combined Treatment With Curettage and Imiquimod for Nodular Basal Cell Carcinoma

Condition:   Nodular Basal Cell Carcinoma
Interventions:   Drug: Imiquimod 5% cream with prior curettage;   Procedure: Standard surgical excision
Sponsor:   Maastricht University Medical Center
Active, not recruiting
Wed, 17 Sep 2014 12:00:00 EDT

Topical Imiquimod for Bowen's Disease of the Head and Neck

Condition:   Bowens Disease
Intervention:   Drug: Imiquimod
Sponsor:   Brooke Army Medical Center
Unknown status
Thu, 05 Oct 2006 12:00:00 EDT

Safety, Tolerability, and Immunogenicity of GTL001 Vaccine Adjuvanted With Imiquimod Cream in HPV 16- and/or HPV 18-Infected Women Aged 25 to 65 Years, With Normal Cytology, ASCUS, or LSIL

Condition:   HPV 16- and/or HPV 18-Infected Women With Normal Cytology, ASCUS, or LSIL
Interventions:   Drug: GTL001+;   Drug: Aldara
Sponsors:   Genticel;   PPD
Terminated
Wed, 24 Feb 2016 12:00:00 EST

Imiquimod Treatment of Residual or Recurrent CIN Lesions: a Study Protocol

Condition:   Cervical Intraepithelial Neoplasia
Interventions:   Drug: Imiquimod;   Procedure: LLETZ
Sponsors:   Erasmus Medical Center;   Maastricht University Medical Center;   Meander Medisch Centrum;   Albert Schweitzer Hospital;   Sint Franciscus Gasthuis;   Catharina Ziekenhuis Eindhoven
Unknown status
Mon, 01 Feb 2016 12:00:00 EST

Imiquimod Treatment of CIN Lesions

Condition:   Cervical Intraepithelial Neoplasia
Interventions:   Drug: Imiquimod;   Procedure: LLETZ
Sponsors:   Maastricht University Medical Center;   MEDA Pharma GmbH & Co. KG
Terminated
Wed, 31 Dec 2014 12:00:00 EST

Cellular and Molecular Events During Treatment of Actinic Keratosis With Imiquimod 5% Cream

Condition:   Actinic Keratosis
Interventions:   Drug: Aldara (imiquimod 5% cream);   Drug: Vehicle cream
Sponsor:   Graceway Pharmaceuticals, LLC
Completed
Fri, 09 Jun 2006 12:00:00 EDT

Primary Imiquimod Treatment Versus Surgery for Vulvar Intraepithelial Neoplasia

Condition:   Vulvar Intraepithelial Neoplasia
Interventions:   Drug: Imiquimod;   Procedure: Surgery
Sponsors:   Medical University of Graz;   Austrian Science Fund (FWF)
Completed
Thu, 23 May 2013 12:00:00 EDT

Adjuvant Anal Imiquimod Therapy in Anal HPV-lesions: AdAM-trial

Conditions:   Anogenital Human Papillomavirus Infection;   Condyloma Anal
Interventions:   Drug: Imiquimod 5% cream;   Drug: Placebo cream;   Procedure: Fulguration
Sponsor:   Medical University Innsbruck
Not yet recruiting
Wed, 20 Sep 2017 12:00:00 EDT

Immunevasion of Human Papillomavirus (HPV) in Vulvar Intraepithelial Neoplasia 2/3 and Anogenital Warts and Efficiency and Mechanisms of Imiquimod Treatment

Condition:   HPV
Intervention:   Drug: Imiquimod
Sponsor:   Medical University of Vienna
Completed
Mon, 20 Jul 2009 12:00:00 EDT

Topical Aldara (Imiquimod) for Oral Cancer

Condition:   Oral Cancer
Intervention:   Drug: Imiquimod 5% Cream,Top,Pkt,0.25Gm
Sponsor:   Columbia University
Recruiting
Wed, 12 May 2021 12:00:00 EDT

Bioequivalence of Generic Imiquimod Cream, 5% When Compared to Aldara™ (Imiquimod) Cream, 5% in the Treatment of Actinic Keratosis

Condition:   Actinic Keratoses
Interventions:   Drug: imiquimod;   Drug: Aldara™;   Drug: Vehicle Cream
Sponsor:   Actavis Inc.
Completed
Wed, 29 Jul 2009 12:00:00 EDT

Risk of Squamous Cell Carcinoma on Skin Areas Treated With Ingenol Mebutate Gel, 0.015% and Imiquimod Cream, 5%

Condition:   Actinic Keratosis (AK)
Interventions:   Drug: Ingenol Mebutate Gel, 0.015%;   Drug: Imiquimod Cream, 5%
Sponsor:   LEO Pharma
Completed
Wed, 21 Aug 2013 12:00:00 EDT

Treatment of Actinic Keratoses of the Face With Imiquimod 3.75% Cream Followed by Photodynamic Therapy

Condition:   Actinic Keratosis
Interventions:   Drug: Photodynamic therapy;   Drug: Imiquimod
Sponsors:   Tennessee Clinical Research Center;   Graceway Pharmaceuticals, LLC
Terminated
Fri, 17 Sep 2010 12:00:00 EDT

Photoaging Treatment With Imiquimod

Condition:   Photoaging
Intervention:   Drug: Imiquimod
Sponsor:   CES University
Completed
Thu, 05 Sep 2013 12:00:00 EDT

Combining Topical Imiquimod 5% Cream With a Pulsed Dye Laser to Treat Port Wine Stain Birthmarks

Condition:   Port Wine Stain
Interventions:   Drug: Imiquimod;   Other: Placebo
Sponsors:   University of California, Irvine;   Beckman Laser Institute University of California Irvine
Completed
Thu, 03 Jan 2008 12:00:00 EST

Imiquimod/Brain Tumor Initiating Cell (BTIC) Vaccine in Brain Stem Glioma

Condition:   Diffuse Intrinsic Pontine Glioma
Interventions:   Biological: Tumor Lysate Vaccine;   Drug: Imiquimod;   Radiation: Radiation therapy
Sponsor:   Masonic Cancer Center, University of Minnesota
Terminated
Fri, 22 Jul 2011 12:00:00 EDT

Topical Imiquimod in Conjunction With Nd:YAG Laser for Tattoo Removal

Condition:   Healthy
Interventions:   Device: 1064 nm Nd:YAG laser;   Drug: Imiquimod, 5% cream
Sponsors:   University of Miami;   Graceway Pharmaceuticals, LLC
Completed
Wed, 19 Mar 2008 12:00:00 EDT

Effect of Topical Imiquimod on Lentigo Maligna

Condition:   Lentigo Maligna
Intervention:   Drug: Imiquimod
Sponsors:   Jerry Marsden;   Department of Health, United Kingdom
Completed
Wed, 14 Jul 2010 12:00:00 EDT

Cyclophosphamide, TAPA-Pulsed Dendritic Cell Therapy and Imiquimod in Progressive and/or Refractory Solid Malignancies

Conditions:   Progressive Solid Malignancies;   Refractory Solid Malignancies;   Cancer
Interventions:   Biological: TAPA-pulsed DC vaccine;   Drug: Cyclophosphamide Pill;   Drug: Imiquimod Topical Cream
Sponsor:   Kiromic, Inc.
Terminated
Mon, 25 Aug 2014 12:00:00 EDT

Intralesional 5-Fluorouracil (5FU), Topical Imiquimod Treatment for SCC

Condition:   Carcinoma, Squamous Cell
Interventions:   Drug: 5-fluorouracil;   Drug: Imiquimod 5% cream
Sponsors:   Melissa Pugliano-Mauro;   National Cancer Institute (NCI)
Recruiting
Tue, 12 Dec 2017 12:00:00 EST

Imiquimod 5% Cream in the Treatment of External Genital or Perianal Warts in HIV+ Patients

Condition:   Warts
Intervention:   Drug: Imiquimod 5% cream
Sponsors:   MEDA Pharma GmbH & Co. KG;   ORION Sante
Completed
Mon, 29 Sep 2008 12:00:00 EDT

Imiquimod and Tumor Lysate Vaccine Immunotherapy in Adults With High Risk or Recurrent Grade II Gliomas

Conditions:   High Risk WHO Grade II Glioma;   Recurrent/Post-Chemotherapy WHO Grade II Glioma
Interventions:   Biological: Tumor Lysate Vaccine;   Drug: Imiquimod
Sponsors:   Frank Lieberman;   University of Minnesota
Completed
Wed, 05 Sep 2012 12:00:00 EDT

Imiquimod Treatment of High-grade CIN

Condition:   Cervical Intraepithelial Neoplasia
Interventions:   Drug: Imiquimod;   Procedure: Large Loop Excision of the Transformation Zone
Sponsors:   Maastricht University Medical Center;   Clinical Trial Center Maastricht B.V.
Unknown status
Wed, 28 Sep 2016 12:00:00 EDT

Study of Immune Responses to Influenza Vaccination With or Without Imiquimod Application in Untreated CLL Patients

Condition:   Chronic Lymphocytic Leukemia
Interventions:   Drug: Imiquimod cream;   Drug: influenza vaccine
Sponsors:   The Royal Bournemouth Hospital;   CLL Topics, Inc.
Terminated
Thu, 17 Jan 2008 12:00:00 EST

Topical Fluorouracil and Imiquimod in Treating Patients With High-Grade Cervical Intraepithelial Neoplasia

Conditions:   Cervical Intraepithelial Neoplasia Grade 2/3;   Cervical Squamous Cell Carcinoma In Situ;   Cervical Squamous Intraepithelial Neoplasia 2;   High Grade Cervical Intraepithelial Neoplasia
Interventions:   Drug: Imiquimod;   Drug: Topical Fluorouracil
Sponsor:   National Cancer Institute (NCI)
Active, not recruiting
Thu, 22 Jun 2017 12:00:00 EDT

Phase 3 Study of Imiquimod Creams in the Treatment of External Genital Warts

Condition:   Genital Warts
Interventions:   Drug: 2.5% imiquimod cream;   Drug: 3.75% imiquimod cream;   Drug: Placebo cream
Sponsor:   Graceway Pharmaceuticals, LLC
Completed
Fri, 15 Aug 2008 12:00:00 EDT

Safety and Effectiveness Study of Imiquimod Creams in the Treatment of External Genital Warts

Condition:   Genital Warts
Interventions:   Drug: Imiquimod;   Drug: 3.75% imiquimod cream;   Drug: placebo cream
Sponsor:   Graceway Pharmaceuticals, LLC
Completed
Thu, 08 May 2008 12:00:00 EDT

Genomic Markers Before and After Treatment of Actinic Keratosis With Imiquimod 3.75% Cream

Condition:   Actinic Keratosis
Intervention:   Drug: Imiquimod 3.75% Cream
Sponsors:   Icahn School of Medicine at Mount Sinai;   Bausch Health Americas, Inc.
Completed
Tue, 16 Apr 2019 12:00:00 EDT

A Study to Evaluate the Effectiveness of Imiquimod 5% Cream for Basal Cell Carcinoma Recurrence

Condition:   Basal Cell Carcinoma
Intervention:   Drug: Imiquimod 5% cream
Sponsor:   Graceway Pharmaceuticals, LLC
Completed
Fri, 12 Aug 2005 12:00:00 EDT

A Study to Evaluate the Safety and Efficacy Imiquimod Cream, 2.5% in Participants With Actinic Keratoses

Condition:   Actinic Keratosis
Interventions:   Drug: Imiquimod;   Drug: Zyclara®;   Drug: Vehicle Cream
Sponsor:   Actavis Inc.
Completed
Wed, 23 Apr 2014 12:00:00 EDT

Topical Imiquimod 5% Cream for Treatment of Cutaneous Neurofibromas in Adults With Neurofibromatosis 1

Conditions:   Neurofibromatosis Type 1;   Cutaneous Neurofibromas
Intervention:   Drug: Imiquimod 5% Cream
Sponsor:   Massachusetts General Hospital
Completed
Thu, 19 Mar 2009 12:00:00 EDT

Aldara for the Treatment of Large and/or Multiple sBCC

Condition:   Carcinoma, Basal Cell
Intervention:   Drug: Imiquimod
Sponsor:   MEDA Pharma GmbH & Co. KG
Completed
Mon, 19 Sep 2005 12:00:00 EDT

Clinical Study to Evaluate the Bioequivalence of Two Imiquimod Cream 3.75% Formulations in Patients With Actinic Keratosis.

Condition:   Actinic Keratosis
Interventions:   Drug: Imiquimod Topical Cream 3.75%;   Drug: Zyclara® (imiquimod) Topical Cream 3.75%;   Drug: Vehicle Topical Cream
Sponsor:   Taro Pharmaceuticals USA
Completed
Mon, 11 Feb 2013 12:00:00 EST

Effectiveness of Imiquimod Topical Cream in Early Stage Cutaneous T-cell Lymphoma

Condition:   Mycosis Fungoides
Interventions:   Drug: 3.75% Imiquimod Cream;   Drug: 0.1% Fluocinonide Cream
Sponsors:   Rochester General Hospital;   Bausch Health Americas, Inc.;   Rochester Skin Lymphoma Medical Group, PLLC
Withdrawn
Wed, 26 Nov 2014 12:00:00 EST

H5N1 With or Without Topical Aldara in Healthy Adults

Conditions:   Avian Influenza;   Influenza Immunisation
Interventions:   Other: Aqueous Cream B.P.;   Drug: Imiquimod;   Biological: Influenza Virus Vaccine, Monovalent A/H5N1 A/Vietnam/1203/04
Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
Completed
Wed, 21 Mar 2018 12:00:00 EDT

A Study to Evaluate Neoadjuvant Sonidegib Followed by Surgery or Imiquimod in the Management of Basal Cell Carcinoma

Conditions:   Basal Cell Carcinoma;   Basal Cell Carcinoma of Skin, Site Unspecified;   Skin Cancer;   Invasive Carcinoma
Interventions:   Drug: Sonidegib;   Drug: Imiquimod;   Procedure: Surgery;   Other: Best supportive care
Sponsor:   Melanoma Institute Australia
Recruiting
Wed, 23 May 2018 12:00:00 EDT

Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma

Conditions:   Metastatic Melanoma;   Stage IIIB Cutaneous Melanoma AJCC v7;   Stage IIIC Cutaneous Melanoma AJCC v7;   Stage IV Cutaneous Melanoma AJCC v6 and v7
Interventions:   Drug: Imiquimod;   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab
Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
Active, not recruiting
Fri, 08 Sep 2017 12:00:00 EDT

Characteristics of T Cells From Alopecia Areata Scalp Skin Before and After Treatment With Aldara 5%

Condition:   Alopecia Areata
Intervention:   Drug: Aldara Cream 5%
Sponsors:   Hordinsky, Maria K., MD;   National Alopecia Areata Foundation
Completed
Thu, 15 Sep 2005 12:00:00 EDT

Imiquimod and Influenza Vaccine for Immunocompromised Patients

Condition:   Influenza Vaccine
Interventions:   Biological: Intanza;   Biological: Mutagrip;   Drug: Aldara
Sponsor:   University of Lausanne Hospitals
Completed
Thu, 10 Nov 2016 12:00:00 EST

Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis

Condition:   Actinic Keratosis
Interventions:   Drug: Imiquimod Cream, 3.75%;   Drug: Zyclara®;   Other: Vehicle of Test Product
Sponsor:   Teva Pharmaceuticals USA
Completed
Mon, 17 Sep 2012 12:00:00 EDT

Betaglucin 0.2% Versus Imiquimod 5% in Treatment of Ano-genital Warts: Combined Results From Triple Blind Controlled Study

Condition:   Genital Wart Virus Infection
Interventions:   Drug: Betaglucin soluble gel 0.2%;   Drug: Imiquimod 5% cream
Sponsors:   Centro de Investigaciones Medicas y Ensayos Clinicos Dr Italo Fabbri;   CALOX Laboratories;   Bioanalisis
Recruiting
Wed, 03 Apr 2019 12:00:00 EDT

ID HBV Vaccination With Imiquimod in OBI

Condition:   Hepatitis B
Interventions:   Biological: Imiquimod + ID HBVv;   Biological: Aqueous + ID HBVv;   Biological: Imiquimod + IM HBVv
Sponsor:   The University of Hong Kong
Completed
Thu, 12 Oct 2017 12:00:00 EDT

Bioequivalence Study of Two Imiquimod Cream 5%

Condition:   Actinic Keratosis
Interventions:   Drug: Imiquimod 5% manufactured by Taro;   Drug: Aldara - Imiquimod 5%;   Drug: Imiquimod Vehicle manufactured by Taro
Sponsor:   Taro Pharmaceuticals USA
Completed
Mon, 26 Jan 2009 12:00:00 EST

Evaluation of Two Different Non-Invasive Techniques to Monitor the Clearance of Actinic Keratosis Lesions

Condition:   Actinic Keratosis
Interventions:   Drug: Aldara (Imiquimod);   Other: Vehicle cream
Sponsor:   MEDA Pharma GmbH & Co. KG
Completed
Wed, 22 Feb 2006 12:00:00 EST

Intron-A/Aldara Combination Therapy for Basal Cell Carcinoma (BCC)

Condition:   Basal Cell Carcinoma
Intervention:   Biological: Imiquimod and Interferon alpha
Sponsor:   The University of Texas Health Science Center, Houston
Completed
Thu, 27 Dec 2007 12:00:00 EST

Safety and Efficacy of GX-188E Administered Via EP Plus GX-I7 or Imiquimod.

Condition:   Cervical Intraepithelial Neoplasia 3
Interventions:   Biological: GX-188E, GX-I7;   Biological: GX-188E, Imiquimod
Sponsors:   Seoul St. Mary's Hospital;   Genexine, Inc.
Unknown status
Sun, 02 Jul 2017 12:00:00 EDT

Study of Imiquimod Cream Prior to Ablative Therapy in External Ano-Genital Warts

Condition:   Genital Warts
Interventions:   Drug: Imiquimod;   Other: vehicle cream
Sponsor:   MEDA Pharma GmbH & Co. KG
Completed
Mon, 19 Sep 2005 12:00:00 EDT

Topical Imiquimod in Treating Patients With Recurrent Paget's Disease of the Vulva

Condition:   Vulvar Cancer
Interventions:   Drug: imiquimod;   Procedure: biopsy;   Procedure: therapeutic conventional surgery
Sponsors:   Memorial Sloan Kettering Cancer Center;   National Cancer Institute (NCI);   Ohio State University
Completed
Thu, 19 Jul 2007 12:00:00 EDT

Anal Dysplasia Study of Men Who Have Sex With Men Living With HIV

Conditions:   Anal Dysplasia;   Human Papilloma Virus;   HIV
Interventions:   Drug: imiquimod;   Procedure: ablative
Sponsor:   United States Naval Medical Center, San Diego
Withdrawn
Mon, 13 Aug 2012 12:00:00 EDT

Earliest Stage Treatment of Aktinic Keratosis With Imiquimod 3.75% Cream

Condition:   Actinic Keratoses
Intervention:   Drug: Imiquimod 3.75% Cream
Sponsor:   Medical University of Graz
Recruiting
Tue, 13 Apr 2021 12:00:00 EDT

Intradermal Influenza Vaccine With Topical Imiquimod in Elderly and Chronic Illness Patients

Condition:   Influenza
Interventions:   Biological: Vaxigrip tetra;   Biological: Fluzone high-dose;   Drug: Aldara 5% Topical Cream;   Drug: Aqueous cream BP
Sponsor:   The University of Hong Kong
Recruiting
Tue, 29 Oct 2019 12:00:00 EDT

Treatment of Primary Basal Cell Carcinomas of the Skin With Combination of Topical Imiquimod and Cryosurgery

Condition:   Basal Cell Carcinoma
Intervention:   Procedure: Immunocryosurgery
Sponsor:   University of Ioannina
Completed
Thu, 30 Sep 2010 12:00:00 EDT

Intra-dermal With Topical Imiquimod Pretreatment Versus Intra-muscular Hepatitis B Vaccination in IBD Patients

Conditions:   Inflammatory Bowel Diseases;   Hepatitis B
Interventions:   Biological: Intradermal hepatitis B vaccine with imiquimod;   Biological: Intramuscular hepatitis B vaccine with aqueous cream
Sponsor:   The University of Hong Kong
Active, not recruiting
Tue, 10 Sep 2019 12:00:00 EDT

Randomized Clinical Trial Evaluating the Efficacy of Topical Imiquimod in High Grade Cervical Intraepithelial Lesions

Conditions:   High Grade Intraepithelial Neoplasia;   Cervix Cancer
Interventions:   Procedure: Control;   Drug: Imiquimod
Sponsors:   Barretos Cancer Hospital;   Farmoquimica S.A.
Completed
Fri, 28 Jul 2017 12:00:00 EDT

Imiquimod in Children With Plaque Morphea

Condition:   Scleroderma, Localized
Intervention:   Drug: Imiquimod 5% cream
Sponsor:   The Hospital for Sick Children
Completed
Wed, 07 Sep 2005 12:00:00 EDT

Evaluation of Intradermal Hepatitis B Vaccine After IMIQUIMOD's Application, in Cirrhotics Who Did Not Respond to the Usual Vaccine Regimen

Conditions:   Cirrhosis, Liver;   Vaccination Failure;   HBV;   Vaccine Reaction
Interventions:   Drug: IMIQUIMOD cream;   Biological: HEPATITIS B SURFACE ANTIGEN
Sponsor:   Central Hospital, Nancy, France
Not yet recruiting
Tue, 31 Aug 2021 12:00:00 EDT

Long-term Effects of Imiquimod and Diclofenac in Actinic Keratoses (LEIDA 2)

Condition:   Actinic Keratosis
Interventions:   Drug: Imiquimod;   Drug: Diclofenac
Sponsors:   MEDA Pharma GmbH & Co. KG;   Siro Clinpharm Germany GmbH (until June 2013);   Accovion GmbH
Completed
Mon, 17 Oct 2011 12:00:00 EDT

Relevance of Imiquimod as Neo-adjuvant Treatment to Reduce Excision Size and the Risk of Intralesional Excision in Lentigo Malignant of the Face

Condition:   Lentigo Maligna Melanoma (Head or Neck)
Interventions:   Drug: Imiquimod cream + surgery;   Drug: Placebo + surgery
Sponsors:   Nantes University Hospital;   MEDA Pharma GmbH & Co. KG
Active, not recruiting
Fri, 02 Nov 2012 12:00:00 EDT

Efficacy and Tolerability of Topical LFX453 for External Genital Warts

Condition:   External Genital Warts
Interventions:   Drug: Investigational Treatment;   Drug: Aldara
Sponsor:   Novartis Pharmaceuticals
Completed
Fri, 26 Jun 2015 12:00:00 EDT

A Study to Evaluate Effectiveness of Imiquimod 5% Cream in Superficial Basal Cell Carcinoma

Condition:   Basal Cell Carcinoma
Intervention:   Drug: imiquimod
Sponsor:   MEDA Pharma GmbH & Co. KG
Completed
Mon, 19 Sep 2005 12:00:00 EDT

Imiquimod, Fluorouracil, or Observation in Treating HIV-Positive Patients With High-Grade Anal Squamous Skin Lesions

Conditions:   Anal Intraepithelial Neoplasia;   High-grade Squamous Intraepithelial Lesion;   HIV Infection
Interventions:   Drug: imiquimod;   Drug: fluorouracil;   Other: questionnaire administration;   Other: laboratory biomarker analysis
Sponsors:   AIDS Malignancy Consortium;   National Cancer Institute (NCI);   The Emmes Company, LLC;   University of Arkansas
Recruiting
Tue, 11 Feb 2014 12:00:00 EST

Imiquimod 5% Cream for the Treatment of Periocular Basal Cell Carcinoma

Condition:   Carcinoma, Basal Cell
Intervention:   Drug: Imiquimod 5% cream
Sponsor:   University of Sao Paulo
Unknown status
Mon, 08 Dec 2008 12:00:00 EST

Treatment of Nodular Basal Cell Carcinoma (BCC) With Imiquimod 5% Cream After Curettage

Condition:   Basal Cell Carcinoma
Intervention:   Drug: imiquimod
Sponsor:   Wake Forest University
Completed
Fri, 14 Apr 2006 12:00:00 EDT

Mechanistically-based Optimization of UV Radiation Therapy in Psoriasis

Condition:   Psoriasis
Interventions:   Drug: Imiquimod;   Drug: Clobetasol
Sponsors:   VA Office of Research and Development;   University Hospitals Cleveland Medical Center
Terminated
Mon, 07 May 2007 12:00:00 EDT

Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3)

Conditions:   Vulvar High Grade Squamous Intraepithelial Lesion (HSIL);   Vulvar Dysplasia;   Vulvar Intraepithelial Neoplasia (VIN);   VIN2;   VIN3;   Pre-cancerous Lesions of the Vulva;   Human Papillomavirus (HPV)
Interventions:   Biological: VGX-3100;   Drug: Imiquimod 5% cream;   Device: CELLECTRA™ 2000
Sponsor:   Inovio Pharmaceuticals
Completed
Thu, 08 Jun 2017 12:00:00 EDT

Combination Therapy With Imiquimod Cream 5% and Tazarotene Cream 0.1% for the Treatment of Lentigo Maligna

Conditions:   Cancer;   Lentigo Maligna
Interventions:   Drug: Imiquimod Cream;   Drug: Tazarotene Cream 0.1%
Sponsor:   University of Utah
Completed
Mon, 30 Jun 2008 12:00:00 EDT

Imiquimod 5% Cream in Plaque-type Morphea: A Pilot, Prospective Open-label Study

Condition:   Morphea
Intervention:   Drug: imiquimod 5% cream (Aldara)
Sponsors:   University of Alberta;   3M
Withdrawn
Fri, 30 Sep 2005 12:00:00 EDT

A Study to Evaluate the Effectiveness and Safety of Multiple Applications of Imiquimod 5% Cream for the Treatment of Actinic Keratoses in Organ Transplant Recipients

Condition:   Actinic Keratosis
Intervention:   Drug: Imiquimod 5 % Cream
Sponsor:   MEDA Pharma GmbH & Co. KG
Completed
Mon, 19 Sep 2005 12:00:00 EDT

Long-term Effects of Imiquimod and Diclofenac in Actinic Keratoses

Condition:   Actinic Keratosis
Interventions:   Drug: Imiquimod;   Drug: Diclofenac
Sponsor:   MEDA Pharma GmbH & Co. KG
Completed
Wed, 22 Oct 2008 12:00:00 EDT

Imiquimod in Preventing Cervical Cancer in Women With Cervical Neoplasia

Conditions:   Cervical Cancer;   Precancerous Condition
Interventions:   Drug: imiquimod;   Procedure: Ablative or excisional therapy
Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
Completed
Mon, 27 Jan 2003 12:00:00 EST

Evaluation of the Impact of Adjuvants Accompanying Peptide Immunization in High-Risk Melanoma

Condition:   High-Risk Melanoma
Interventions:   Drug: gp100:209-217 (210M);   Drug: Montanide ISA-51;   Drug: Imiquimod
Sponsor:   National Cancer Institute (NCI)
Completed
Mon, 09 Jan 2006 12:00:00 EST

Imiquimod Plus Antimony Immunochemotherapy for Cutaneous Leishmaniasis

Condition:   Cutaneous Leishmaniasis
Intervention:   Drug: Imiquimod
Sponsor:   Drugs for Neglected Diseases
Completed
Wed, 23 Nov 2005 12:00:00 EST

A Bioequivalence Study With Clinical Endpoints Comparing Generic Imiquimod Cream, 3.75% and Zyclara™ (Imiquimod) Cream, 3.75% in Subjects With Actinic Keratoses

Condition:   Actinic Keratoses
Interventions:   Drug: imiquimod cream, 3.75%;   Drug: Vehicle Cream
Sponsor:   Actavis Mid-Atlantic LLC
Completed
Fri, 30 Dec 2011 12:00:00 EST

Dendritic Cell Vaccine With Imiquimod for Patients With Malignant Glioma

Condition:   Malignant Glioma
Intervention:   Biological: Dendritic Cell Vaccine in combination with Imiquimod cream
Sponsor:   Cedars-Sinai Medical Center
Completed
Fri, 15 Feb 2013 12:00:00 EST

Potential Effect of Topical Imiquimod on Atrial Ectopy in Patients With Actinic Keratosis

Condition:   Actinic Keratosis
Interventions:   Drug: Imiquimod cream 3.75%;   Drug: Placebo cream
Sponsor:   Medicis Global Service Corporation
Unknown status
Wed, 10 Aug 2011 12:00:00 EDT

Study of Imiquimod 5% Cream in Addition to Cryotherapy in the Management of Actinic Keratoses

Conditions:   Keratosis;   Actinic Keratosis
Intervention:   Drug: Imiquimod used as an adjunct to cryotherapy
Sponsors:   Derm Research @ 888 Inc.;   3M
Completed
Fri, 13 May 2005 12:00:00 EDT

Safety and Efficacy Study of Imiquimod 5% Cream Applied 3x Per Week for 8 or 12 Weeks in Low Risk Nodular Basal Cell Carcinoma

Condition:   Carcinoma, Basal Cell
Intervention:   Drug: Imiquimod
Sponsor:   University Hospital Tuebingen
Completed
Tue, 20 Sep 2005 12:00:00 EDT

Safety and Effectiveness Study of Actinic Keratosis Treatment Following Cryosurgery

Condition:   Actinic Keratosis
Interventions:   Drug: imiquimod cream;   Drug: placebo cream
Sponsor:   Graceway Pharmaceuticals, LLC
Completed
Thu, 07 May 2009 12:00:00 EDT

Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors

Conditions:   Melanoma;   Breast Cancer;   Merkel Cell Carcinoma;   Squamous Cell Cancer;   Non Small Cell Lung Cancer;   Cervical Cancer;   Urothelial Carcinoma;   Ovarian Cancer;   Hepatocellular Carcinoma;   Small-cell Lung Cancer;   Microsatellite Instability High;   Gastric Cancer;   Esophageal Cancer
Interventions:   Device: Echopulse;   Drug: Imiquimod;   Drug: Standard of Care PD-1 Therapy
Sponsors:   Craig L Slingluff, Jr;   Theraclion
Recruiting
Fri, 04 Oct 2019 12:00:00 EDT

Topical Application of Imiquimod Gel at Different Concentrations in Actinic Cheilitis

Condition:   Actinic Cheilitis
Interventions:   Drug: Vehicle Gel Base;   Drug: Imiquimod 5% gel;   Drug: Imiquimod 0,05% gel;   Drug: Imiquimod nanoencapsulated 0,05% gel;   Drug: Lip sunscreen 30 Sun Protector Factor (SPF);   Drug: Dexpanthenol
Sponsors:   Hospital de Clinicas de Porto Alegre;   Federal University of Rio Grande do Sul
Recruiting
Tue, 07 Jan 2020 12:00:00 EST

Safety and Effectiveness Study of Imiquimod Creams for Treatment of Actinic Keratoses (AKs)

Condition:   Actinic Keratoses
Interventions:   Drug: imiquimod cream;   Drug: Placebo
Sponsor:   Graceway Pharmaceuticals, LLC
Completed
Wed, 30 Jan 2008 12:00:00 EST

Intradermal Trivalent Influenza Vaccine With Imiquimod

Condition:   Chronic Illness
Interventions:   Biological: influenza vaccine;   Drug: Imiquimod;   Drug: Aqueous cream
Sponsor:   The University of Hong Kong
Completed
Thu, 12 Jan 2012 12:00:00 EST

Safety and Effectiveness Study of Imiquimod Creams for the Treatment of Actinic Keratoses (AKs)

Condition:   Actinic Keratosis
Interventions:   Drug: Imiquimod cream;   Drug: Placebo cream
Sponsor:   Graceway Pharmaceuticals, LLC
Completed
Tue, 29 Jan 2008 12:00:00 EST

Toll-like Receptor (TLR) 7 Agonist, Cyclophosphamide, and Radiotherapy for Breast Cancer With Skin Metastases

Conditions:   Breast Cancer;   Metastatic Breast Cancer;   Recurrent Breast Cancer
Interventions:   Radiation: Radiation;   Drug: Imiquimod;   Drug: Cyclophosphamide
Sponsors:   NYU Langone Health;   National Cancer Institute (NCI)
Completed
Mon, 22 Aug 2011 12:00:00 EDT

Oral Miltefosine Plus Topical Imiquimod to Treat Cutaneous Leishmaniasis

Condition:   Cutaneous Leishmaniasis
Interventions:   Drug: Miltefosine + Imiquimod;   Drug: Miltefosine 150 mg x day + Placebo
Sponsor:   Foundation Fader
Completed
Mon, 27 Jun 2011 12:00:00 EDT

Vaccination With Dendritic Cells Loaded With Brain Tumor Stem Cells for Progressive Malignant Brain Tumor

Conditions:   Brain Tumor;   Glioblastoma;   Medulloblastoma;   Ependymoma;   Anaplastic Astrocytoma
Interventions:   Biological: Dendritic Cells;   Drug: Imiquimod
Sponsor:   Masonic Cancer Center, University of Minnesota
Completed
Wed, 28 Jul 2010 12:00:00 EDT

Imiquimod Cream in Treating Patients With Basal Cell Skin Cancer

Condition:   Non-melanomatous Skin Cancer
Interventions:   Drug: imiquimod;   Procedure: conventional surgery
Sponsor:   National Naval Medical Center
Completed
Wed, 10 Mar 2004 12:00:00 EST

A Double-blind, Randomized, Single Centre, Vehicle-controlled Study to Evaluate the Safety and Tolerability of a New Topical Formulation Containing 0,09% Imiquimod (Limtop) in Healthy Subjects

Condition:   Healthy
Intervention:   Drug: Imiquimod (topical use)
Sponsor:   Moberg Pharma AB
Completed
Fri, 30 Mar 2012 12:00:00 EDT

A MultIceNTER Phase I Peptide VaCcine Trial for the Treatment of H3-Mutated Gliomas

Condition:   Newly Diagnosed H3-mutated Glioma
Interventions:   Drug: Tecentriq 1200 MG in 20 ML Injection;   Biological: H3K27M peptide vaccine;   Other: Imiquimod (5%)
Sponsors:   German Cancer Research Center;   Johannes Gutenberg University Mainz;   Charite University, Berlin, Germany;   Roche Pharma AG;   German Cancer Aid
Not yet recruiting
Mon, 22 Mar 2021 12:00:00 EDT

Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With Granulocyte Macrophage Colony-stimulating Factor (GM-CSF) and Imiquimod

Conditions:   Ovarian Cancer;   Primary Peritoneal Cancer;   Fallopian Tube Cancer
Interventions:   Drug: GM-CSF;   Biological: Dendritic Cell/Tumor Fusion Vaccine;   Drug: imiquimod
Sponsors:   Beth Israel Deaconess Medical Center;   Dana-Farber Cancer Institute;   Brigham and Women's Hospital;   Massachusetts General Hospital;   National Cancer Institute (NCI)
Active, not recruiting
Thu, 27 Nov 2008 12:00:00 EST

A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled Therapeutic Equivalence Study of Three Imiquimod Cream 5% Treatments for Patients With Actinic Keratosis

Condition:   Actinic Keratosis
Interventions:   Drug: Imiquimod 5%: manufactured by Apotex;   Drug: Adara 5% Cream US;   Drug: Adara 5% Cream Canada;   Drug: Imiquimod Vehicle
Sponsor:   Apotex Inc.
Completed
Tue, 10 Mar 2009 12:00:00 EDT

Identification of Novel Biomarkers of Cervicovaginal Mucosal Inflammation

Conditions:   Vaginal Inflammation;   Vaginal Infections
Interventions:   Drug: Imiquimod;   Other: Placebo;   Drug: Nonoxynol-9
Sponsor:   CONRAD
Completed
Mon, 07 May 2012 12:00:00 EDT

Topical Imiquimod and Abraxane in Treating Patients With Advanced Breast Cancer

Conditions:   Male Breast Cancer;   Recurrent Breast Cancer;   Skin Metastases;   Stage IV Breast Cancer
Interventions:   Drug: imiquimod;   Drug: Abraxane;   Other: laboratory biomarker analysis;   Genetic: RNA analysis;   Other: immunoenzyme technique
Sponsors:   University of Washington;   National Cancer Institute (NCI)
Completed
Wed, 14 Jan 2009 12:00:00 EST

Intradermal Influenza Vaccine in the Young

Condition:   Influenza Viral Infections
Interventions:   Drug: Imiquimod ointment;   Drug: Aqueous cream;   Biological: Intradermal influenza vaccine;   Biological: Intramuscular influenza vaccine
Sponsor:   The University of Hong Kong
Completed
Thu, 03 Apr 2014 12:00:00 EDT

Vaccine Therapy With or Without Imiquimod in Treating Patients With Grade 3 Cervical Intraepithelial Neoplasia

Conditions:   Cervical Cancer;   Precancerous Condition;   HPV Disease;   Human Papilomavirus
Interventions:   Biological: TA-HPV;   Biological: pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine;   Drug: imiquimod
Sponsors:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;   National Cancer Institute (NCI)
Recruiting
Mon, 10 Nov 2008 12:00:00 EST

Topical Imiquimod Compared With Surgery in Treating Patients With Basal Cell Skin Cancer

Condition:   Non-melanomatous Skin Cancer
Interventions:   Drug: imiquimod;   Procedure: conventional surgery
Sponsor:   Queen's Medical Centre
Completed
Thu, 07 Aug 2003 12:00:00 EDT

Topical Challenge With Omiganan and Imiquimod in Healthy Volunteers

Condition:   Healthy
Interventions:   Drug: Omiganan;   Drug: Imiquimod;   Drug: Omiganan 1% and Imiquimod;   Drug: Omiganan 2.5% and Imiquimod;   Drug: Placebo
Sponsor:   Maruho Co., Ltd.
Completed
Tue, 07 Mar 2017 12:00:00 EST

Treatment of High-Grade Pre-Neoplastic Cervical Lesions (CIN 2/3)

Conditions:   Cervical Intraepithelial Neoplasia;   Cervical Dysplasia
Interventions:   Drug: 9-valent HPV vaccine;   Drug: Imiquimod
Sponsor:   Yale University
Recruiting
Thu, 11 Aug 2016 12:00:00 EDT

Combination Vaccine Immunotherapy (DRibbles) for Patients With Definitively-Treated Stage III Non-small Cell Lung Cancer

Condition:   Carcinoma, Non-Small-Cell Lung
Interventions:   Drug: Cyclophosphamide;   Biological: DRibble vaccine;   Drug: Imiquimod;   Drug: GM-CSF;   Biological: HPV vaccine
Sponsors:   UbiVac;   National Cancer Institute (NCI);   Providence Cancer Center, Earle A. Chiles Research Institute;   Providence Health & Services;   Mayo Clinic;   Louisiana State University Health Sciences Center in New Orleans
Completed
Fri, 26 Jul 2013 12:00:00 EDT

Peptide Vaccination Associated With Tumoral Immunomodulation in Patients With Advanced Metastatic Melanoma

Condition:   Metastatic Melanoma
Intervention:   Drug: Vaccine MAGE-3.A1 peptide, or the NA17.A2 peptide + IL-2, IFN-α and GMCSF, Imiquimod.
Sponsor:   Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Terminated
Mon, 30 Aug 2010 12:00:00 EDT

Immunotherapy for Recurrent Ependymomas in Children Using Tumor Antigen Peptides With Imiquimod

Condition:   Ependymoma
Interventions:   Biological: HLA-A2 restricted synthetic tumor antigen;   Drug: Imiquimod;   Other: enzyme-linked immunosorbent assay;   Other: flow cytometry;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis
Sponsors:   Ian F. Pollack, M.D.;   Solving Kids' Cancer;   National Cancer Institute (NCI)
Recruiting
Wed, 20 Feb 2013 12:00:00 EST

Comparison of Five Treatments in Patients With Plantar Warts

Condition:   Plantar Warts
Interventions:   Drug: Salicylate ointment;   Drug: Imiquimod;   Drug: 5-Fluoro-Uracil;   Drug: Cryotherapy
Sponsors:   Assistance Publique - Hôpitaux de Paris;   Society of Dermatology and venerology
Terminated
Fri, 29 Jan 2010 12:00:00 EST

Characterization of the Toll-like Receptor 7-agonist Imiquimod 3.75% as a New Surrogate Model of Itch

Condition:   Itch
Interventions:   Drug: Zyclara 3.75 % Topical Cream;   Drug: Prudoxin;   Other: Histamine;   Other: Cowhage;   Other: L-menthol;   Other: Trans-cinnamaldehyde (CA)
Sponsor:   Aalborg University
Withdrawn
Thu, 09 May 2019 12:00:00 EDT

A Study to Follow up Recurrence Rates of Actinic Keratoses One Year After Completion of Study 1487-IMIQ

Condition:   Actinic Keratoses
Intervention:   Drug: Imiquimod
Sponsor:   MEDA Pharma GmbH & Co. KG
Completed
Mon, 19 Sep 2005 12:00:00 EDT

Efficacy and Safety of a New Topical Formulation With Imiquimod (Limtop) Applied 1, 3 or 7 Times Weekly During 2 x 2 Weeks Treatment for Actinic Keratosis on the Head

Condition:   Actinic Keratosis
Intervention:   Drug: Imiquimod (topical use)
Sponsor:   Moberg Pharma AB
Completed
Tue, 05 Jun 2012 12:00:00 EDT

IM Versus 5-FU Versus IMI Versus MAL-PDT in Treatment of Actinic Keratosis

Condition:   Keratosis, Actinic
Interventions:   Drug: Imiquimod;   Drug: 5-fluorouracil;   Drug: Ingenol mebutate;   Procedure: methylaminolevulinate photodynamic therapy
Sponsor:   Maastricht University Medical Center
Unknown status
Sun, 02 Nov 2014 12:00:00 EDT

IMA910 Plus GM-CSF With Low-dose Cyclophosphamide Pre-treatment in Advanced Colorectal Carcinoma Patients Following a Successful 12 Week First-line Treatment With Oxaliplatin-based Chemotherapy (IMA910-101)

Condition:   Colorectal Carcinoma
Interventions:   Drug: Endoxana, Leukine, IMA910;   Drug: Endoxana, Leukine, IMA910, Aldara
Sponsor:   immatics Biotechnologies GmbH
Completed
Wed, 05 Nov 2008 12:00:00 EST

Comparison of Two Schemes of Cryosurgery and Imiquimod Combination Treatment for Basal Cell Carcinoma

Condition:   Basal Cell Carcinoma
Interventions:   Procedure: Immunocryosurgery;   Procedure: Cryoimmunotherapy
Sponsor:   University of Ioannina
Completed
Thu, 30 Sep 2010 12:00:00 EDT

HER2-Peptide Vaccination of Patients With Solid Tumors

Conditions:   Gastric Cancer;   Breast Cancer
Interventions:   Drug: Cyclophosphamide;   Drug: Sargramostim;   Drug: HER2-Peptid-Vakzine;   Drug: Imiquimod
Sponsor:   Technische Universität München
Completed
Tue, 28 Oct 2014 12:00:00 EDT

Patient-individualized Peptide Vaccination Based on Tumor-specific Mutations in Children and Young Adults With Primary/Relapsed ALL

Condition:   Primary/Relapsed Acute Lymphoblastic Leukemia (ALL) of Childhood, Adolescents and Young Adults
Intervention:   Biological: Individual peptide vaccination with adjuvant GM-CSF and Imiquimod
Sponsors:   University Children's Hospital Tuebingen;   German Cancer Research Center;   Universität Tübingen;   University Hospital Tuebingen
Active, not recruiting
Mon, 18 Jun 2018 12:00:00 EDT

HBV Vaccine in Renal Failure Patients

Condition:   Renal Failure
Interventions:   Biological: Intradermal HBVv with imiquimod;   Biological: Intradermal HBVv with aqueous cream;   Biological: Intramuscular HBVv with aqueous cream
Sponsor:   The University of Hong Kong
Completed
Thu, 03 Dec 2015 12:00:00 EST

iVAC-CLL01: Patient-individualized Peptide Vaccination After First Line Therapy of CLL

Condition:   Leukemia, Chronic Lymphatic
Interventions:   Biological: Peptide Vaccine;   Drug: Imiquimod
Sponsors:   University Hospital Tuebingen;   Robert Bosch Gesellschaft für Medizinische Forschung mbH;   Klinikum Stuttgart;   Marienhospital Stuttgart;   Katharinenhospital Stuttgart
Recruiting
Thu, 16 Jun 2016 12:00:00 EDT

Imiquimod and Actinic Keratoses: an Observational Study

Condition:   Actinic Keratosis
Intervention:  
Sponsors:   Federal University Teaching Hospital, Feldkirch, Austria;   MEDA Pharma GmbH & Co. KG
Completed
Tue, 29 Jun 2010 12:00:00 EDT

Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors

Conditions:   Glioma;   Brain Cancer;   Brain Tumor;   Glioblastoma Multiforme;   High Grade Glioma
Interventions:   Biological: Dendritic Cell Vaccine;   Biological: Tumor Lysate;   Other: Imiquimod;   Procedure: Leukapheresis
Sponsor:   Edward Ziga
Terminated
Thu, 18 Jul 2013 12:00:00 EDT

Photodynamic Therapy Mediated by Topical Application of 5- ALA for the Treatment of Actinic Keratoses

Condition:   Actinic Keratosis
Interventions:   Drug: 5-ALA plus Blu-Light;   Drug: 5-FU, Imiquimod or treatment with cryotherapy
Sponsor:   University of Chicago
Withdrawn
Thu, 25 Dec 2008 12:00:00 EST

Pilot Study of DRibble Vaccine for Prostate Cancer Patients

Condition:   Adenocarcinoma of the Prostate
Interventions:   Drug: Cyclophosphamide;   Biological: DRibble Vaccine;   Biological: HPV Vaccinations;   Drug: Imiquimod
Sponsors:   UbiVac;   Providence Health & Services;   Providence Cancer Center;   Providence Cancer Center, Earle A. Chiles Research Institute
Completed
Tue, 09 Sep 2014 12:00:00 EDT

CTCL Directed Therapy

Condition:   Lymphoma, T-Cell, Cutaneous
Interventions:   Drug: Doxycycline;   Drug: Imiquimod
Sponsor:   James J. Peters Veterans Affairs Medical Center
Unknown status
Mon, 17 Apr 2017 12:00:00 EDT

Dendritic Cell (DC) Vaccine for Malignant Glioma and Glioblastoma

Conditions:   Malignant Glioma;   Glioblastoma Multiforme;   Anaplastic Astrocytoma;   High Grade Glioma
Interventions:   Biological: Dendritic Cell Vaccine;   Biological: Tumor Lysate;   Drug: Imiquimod;   Procedure: Leukapheresis
Sponsor:   Macarena De La Fuente, MD
Active, not recruiting
Mon, 11 Mar 2013 12:00:00 EDT

Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer

Conditions:   Colorectal Adenocarcinoma;   Pancreatic Ductal Adenocarcinoma;   Stage IV Colorectal Cancer AJCC v7;   Stage IV Pancreatic Cancer AJCC v6 and v7;   Stage IVA Colorectal Cancer AJCC v7;   Stage IVB Colorectal Cancer AJCC v7
Interventions:   Drug: Imiquimod;   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab;   Biological: Synthetic Tumor-Associated Peptide Vaccine Therapy
Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
Recruiting
Mon, 09 Nov 2015 12:00:00 EST

Immunologic Profile of Chronically Photodamaged Skin

Conditions:   Photoaged Skin;   Normal Skin
Interventions:   Biological: Candida albicans antigen;   Biological: histamine phosphate;   Biological: imiquimod 5% cream;   Procedure: Tape Stripping
Sponsor:   University of Michigan
Suspended
Mon, 05 Sep 2016 12:00:00 EDT

Peptide-based Glioma Vaccine IMA950 in Patients With Glioblastoma

Condition:   Glioblastoma
Interventions:   Drug: Cyclophosphamide;   Biological: IMA950 plus GM-CSF;   Biological: IMA950;   Drug: Imiquimod
Sponsors:   immatics Biotechnologies GmbH;   National Cancer Institute (NCI)
Terminated
Wed, 27 Jul 2011 12:00:00 EDT

Study With TMX-101 in Patients With Carcinoma In Situ (CIS) Bladder Cancer

Conditions:   Carcinoma in Situ;   Non Muscle Invasive Bladder Cancer
Intervention:   Drug: TMX-101
Sponsor:   Telormedix SA
Completed
Thu, 22 Nov 2012 12:00:00 EST

Imiquimod and Laser Therapy With or Without a Green Dye in Treating Patients With Stage III or Stage IV Melanoma That Has Spread to Other Parts of the Skin

Conditions:   Melanoma (Skin);   Metastatic Cancer
Interventions:   Drug: imiquimod;   Drug: indocyanine green solution;   Other: flow cytometry;   Other: immunologic technique;   Other: laboratory biomarker analysis
Sponsor:   University of Oklahoma
Completed
Wed, 28 Mar 2007 12:00:00 EDT

A Window of Opportunity Phase I Study of UGN-201 in Patients With Bladder Cancer Undergoing Radical Cystectomy Protocol #: 2021-0630

Conditions:   Bladder Cancer;   Bladder
Intervention:   Drug: UGN-201
Sponsor:   M.D. Anderson Cancer Center
Not yet recruiting
Thu, 23 Sep 2021 12:00:00 EDT

Epicutaneous Cryoimmunotherapy Combined With Pembrolizumab for Cutaneous Metastatic Breast Cancer

Condition:   Metastatic Breast Cancer
Interventions:   Device: Epicutaneous cryoimmunotherapy;   Drug: Topical imiquimod;   Drug: Pembrolizumab;   Other: Dermatologic Quality of Life Index;   Other: Functional Assessment of Cancer Therapy;   Drug: Intra-lesional GM-CSF;   Device: Cry-AC;   Procedure: Cutaneous tumor biopsy;   Procedure: Peripheral blood draw for research
Sponsors:   Washington University School of Medicine;   Merck Sharp & Dohme Corp.
Terminated
Tue, 11 Jun 2019 12:00:00 EDT

Dendritic Cell Vaccine for Children and Adults With Sarcoma

Conditions:   Sarcoma;   Soft Tissue Sarcoma;   Bone Sarcoma
Interventions:   Biological: Dendritic Cells Vaccine;   Biological: Lysate of Tumor;   Drug: Gemcitabine;   Drug: Imiquimod;   Procedure: Leukapheresis
Sponsor:   Macarena De La Fuente, MD
Active, not recruiting
Mon, 04 Mar 2013 12:00:00 EST

A Personalized NeoAntigen Cancer Vaccine Combined With Anti-PD-1 in Melanoma

Condition:   Melanoma (Skin)
Interventions:   Drug: Peptide;   Drug: Anti-PD-1;   Drug: rhGM-CSF;   Drug: Imiquimod 5% Topical Cream
Sponsor:   Xiangya Hospital of Central South University
Recruiting
Wed, 28 Aug 2019 12:00:00 EDT

Topical or Ablative Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Squamous Intraepithelial Lesions

Conditions:   Anal Cancer;   High-grade Squamous Intraepithelial Lesion;   HIV Infection;   Human Papilloma Virus Infection
Interventions:   Drug: imiquimod;   Drug: fluorouracil;   Device: infrared photocoagulation therapy;   Device: thermal ablation therapy;   Device: laser therapy;   Other: clinical observation;   Other: laboratory biomarker analysis
Sponsors:   AIDS Malignancy Consortium;   National Cancer Institute (NCI);   The Emmes Company, LLC;   University of Arkansas;   University of California, San Francisco
Recruiting
Mon, 12 May 2014 12:00:00 EDT

Safety and Immunogenicity of CYT004-MelQbG10 Vaccine With and Without Adjuvant in Advanced Stage Melanoma Patients

Condition:   Malignant Melanoma
Interventions:   Biological: CYT004-MelQbG10 + Montanide;   Biological: CYT004-MelQbG10 + Montanide + Imiquimod;   Biological: CYT004-MelQbG10 + Imiquimod;   Biological: CYT004-MelQbG10 intra nodal injection
Sponsor:   Cytos Biotechnology AG
Completed
Thu, 03 Apr 2008 12:00:00 EDT

Therapeutic Vaccination for Patients With HPV16+ Cervical Intraepithelial Neoplasia (CIN2/3)

Conditions:   HPV16 Positive;   Cervical Intraepithelial Neoplasia (CIN 2/3)
Interventions:   Biological: DNA vaccination;   Device: Gene gun vaccine;   Biological: intramuscular vaccination;   Biological: intra-lesional vaccine administration;   Procedure: therapeutic resection of the lesion;   Drug: imiquimod
Sponsors:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;   National Institutes of Health (NIH);   National Cancer Institute (NCI)
Completed
Fri, 02 Oct 2009 12:00:00 EDT

Peptide Vaccine and Temozolomide for Metastatic Melanoma Patients

Condition:   Malignant Melanoma
Intervention:   Drug: Chemotherapy: Temozolomide
Sponsors:   Inge Marie Svane;   Copenhagen University Hospital at Herlev
Terminated
Mon, 05 Mar 2012 12:00:00 EST

A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LFX453

Condition:   Healthy
Interventions:   Drug: LFX453 H1;   Drug: LFX453 L1;   Drug: LFX453 H2;   Drug: LFX453 L2;   Drug: Imiquimod;   Drug: Placebo 1;   Drug: Placebo 2
Sponsor:   Novartis Pharmaceuticals
Completed
Mon, 03 Feb 2014 12:00:00 EST

Vaccine Therapy With or Without Imiquimod in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma

Condition:   Melanoma (Skin)
Interventions:   Biological: incomplete Freund's adjuvant;   Biological: multi-epitope melanoma peptide vaccine;   Biological: sargramostim;   Biological: tetanus toxoid helper peptide;   Drug: dimethyl sulfoxide;   Drug: imiquimod;   Procedure: adjuvant therapy
Sponsors:   Craig L Slingluff, Jr;   National Cancer Institute (NCI)
Completed
Mon, 11 Jul 2005 12:00:00 EDT

The Real Life Topical Field Treatment of Actinic Keratosis Study

Condition:   Actinic Keratosis
Interventions:   Drug: Ingenol mebutate;   Drug: 5-fluorouracil;   Drug: Imiquimod;   Drug: Diclofenac
Sponsor:   LEO Pharma
Completed
Thu, 12 Feb 2015 12:00:00 EST

Phase II Study of HPV Therapeutic Vaccine in HPV Infected Women With Normal Cytology or ASCUS/LSIL

Conditions:   Genital Infection Viral;   HUMAN PAPILLOMA VIRUS
Interventions:   Biological: ProCervix;   Biological: Placebo
Sponsor:   Genticel
Completed
Tue, 08 Oct 2013 12:00:00 EDT

Safety, Tolerability, and Efficacy Study of LFX453 in Actinic Keratosis Patients

Condition:   Actinic Keratosis
Interventions:   Drug: Investigational Treatment;   Drug: Active comparator
Sponsor:   Novartis Pharmaceuticals
Completed
Tue, 31 Mar 2015 12:00:00 EDT

IDO Peptid Vaccination for Stage III-IV Non Small-cell Lung Cancer Patients.

Conditions:   NSCLC;   Lung Cancer
Intervention:   Biological: IDO peptide vaccination
Sponsor:   Inge Marie Svane
Completed
Wed, 13 Oct 2010 12:00:00 EDT

Peptide-specific Vaccination in HLA-A*02 Positive Patients With Biochemical Recurrence After Radical Prostatectomy

Condition:   Recurrent Prostate Cancer
Interventions:   Biological: Peptide vaccine;   Drug: Montanide ISA-51;   Drug: Granulocyte macrophage colony stimulating factor (GM-CSF);   Drug: Imiquimod;   Drug: mRNA;   Drug: Protamin;   Procedure: local hyperthermia
Sponsor:   University Hospital Tuebingen
Unknown status
Fri, 22 May 2015 12:00:00 EDT

A Vaccine Study for High Risk Cancers

Conditions:   Neuroblastoma;   Rhabdomyosarcoma;   Osteogenic Sarcoma
Intervention:   Biological: MAGE-A1, MAGE-A3, and NY-ESO-1 Vaccine
Sponsor:   Penn State University
Withdrawn
Thu, 23 Jul 2009 12:00:00 EDT

A Phase II Randomised Trial of Three Regimens of GX301 Vaccination in Castration-resistant Prostate Cancer

Condition:   Prostate Cancer
Intervention:   Biological: GX301
Sponsors:   Laboratoires Leurquin Mediolanum;   Universita degli Studi di Genova
Completed
Tue, 18 Nov 2014 12:00:00 EST

A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

Conditions:   Solid Tumor;   Colon Cancer;   Cholangiocarcinoma;   Bladder Cancer;   Ovarian Cancer;   Gastric Cancer;   Palpable Subcutaneous Malignant Lesions;   Renal Cell Carcinoma;   Melanoma
Interventions:   Biological: TRK-950;   Drug: Irinotecan;   Drug: Leucovorin;   Drug: 5-FU;   Drug: Gemcitabine;   Drug: Cisplatin;   Drug: Carboplatin;   Biological: Ramucirumab;   Drug: Paclitaxel;   Biological: Nivolumab;   Biological: Pembrolizumab;   Drug: Imiquimod Cream;   Biological: Bevacizumab;   Biological: Ipilimumab
Sponsor:   Toray Industries, Inc
Recruiting
Wed, 13 Mar 2019 12:00:00 EDT

Phase I Trial of IDH1 Peptide Vaccine in IDH1R132H-mutated Grade III-IV Gliomas

Condition:   Glioma
Intervention:   Drug: IDH1 peptide vaccine
Sponsors:   National Center for Tumor Diseases, Heidelberg;   University Hospital Heidelberg;   German Cancer Research Center;   Neuro-Oncology Working Group of the German Cancer Society
Completed
Wed, 27 May 2015 12:00:00 EDT

Evaluation of Viral Status of Patients With Plantar Warts Included in VRAIE Study, Non-responder to Study Treatment

Condition:   Plantar Warts
Intervention:   Genetic: skin flakes collection
Sponsor:   Centre Hospitalier Universitaire de Besancon
Terminated
Wed, 10 Aug 2016 12:00:00 EDT

Primary Tumor Harvest for the Purpose of Possible Use in a Future Clinical Trial in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Conditions:   Ovarian Cancer;   Peritoneal Cancer;   Fallopian Tube Cancer
Intervention:   Procedure: Tumor collection
Sponsors:   Beth Israel Deaconess Medical Center;   Dana-Farber Cancer Institute;   Massachusetts General Hospital;   National Cancer Institute (NCI)
Completed
Wed, 03 Dec 2008 12:00:00 EST

Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma

Condition:   Lung Cancer, Non-Small Cell
Intervention:   Procedure: Collection of tumor and blood samples
Sponsor:   GlaxoSmithKline
Terminated
Wed, 28 May 2008 12:00:00 EDT